Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

2(67%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Active, not recruiting1

Recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

active_not_recruiting133%

recruiting133%

completed133%

Recent Activity

2 active trials

Showing 3 of 3

active_not_recruitingphase_1

A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis

NCT07632976

recruitingphase_1

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT07256301

completedphase_1

A Phase Ia Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of EA5 in Healthy Adult Subjects

NCT07256288

Clinical Trials (3)

Showing 3 of 3 trials

NCT07632976Phase 1

A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis

Active Not Recruiting

NCT07256301Phase 1

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recruiting

NCT07256288Phase 1

A Phase Ia Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of EA5 in Healthy Adult Subjects

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3